Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CPGJ602 plus mFOLFOX6 versus cetuximab plus mFOLFOX6 as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer
CTR20201283Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPGJ602 in colorectal cancer (CRC), sponsored by 3S Guojian Pharmaceutical. Started Dec 2020; status: active.
02
Drugs
CPGJ602
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20201283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201283.